6 Feb 2018

OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of...

BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida.

11 Dec 2017

Institutional Decision to Adopt Y90 TARE with TheraSphere® as...

Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

27 Sep 2017

Mirada Medical signs three-year software development agreement with...

Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant...

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

25 Jul 2017

Vancouver’s EVA Vein Care Now Offers New Varicose Vein Treatment

Minimally Invasive Non-Surgical Procedure Now Available in Time for Summer

16 Jun 2017

ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy...

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans, June 14 to 17.

10 Jun 2017

New study shows IO Loop™ improves patient follow-up, engagement...

Study shows patients treated with TheraSphere® maintain quality of life throughout 90 day post-treatment period

22 May 2017

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower...

OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

19 May 2017

BTG and HealthLoop collaborate on IO Loop™, an exclusive service...

Data from a pilot study using IO Loop™ with TheraSphere® (a 90Y transarterial radioembolisation therapy) will be presented at the World Conference on Interventional Oncology